Experienced Executive Well-Positioned to Drive Product and Company Growth
SALT LAKE CITY, Feb. 21 /PRNewswire/ -- Axial Biotech, a company
revolutionizing spine care through the development of molecular diagnostic and
motion preserving technologies, announced today that it has named Eric K.
Olson as the company's new Executive Vice President of Sales and Marketing.
Axial Biotech intends to launch their first product, a DNA-based
pre-symptomatic and prognostic test to determine the risk for developing
severe scoliosis, later this year.
"On behalf of the Axial Biotech Directors, I am excited to welcome Mr.
Olson, a leader of the highest caliber with an extensive and proven track
record in the medical device industry," said Chairman Kenneth Ward, M.D.
"Olson's experience in management, global sales, and marketing, and his
success in achieving profitable growth in domestic and international medical
markets, make him uniquely qualified among the many candidates we considered
for this position," Dr. Ward stated.
Olson comes equipped with 18 years of successful experience in sales and
marketing within the medical device industry. He has led top-producing sales
and marketing teams in organizations ranging from pre-IPO start-ups to Fortune
500 companies.
Prior to his Axial Biotech experience, he was Vice President of Sales and
Marketing for Facet Solutions, Inc. Facet Solutions designed and developed the
Anatomic Facet Replacement System (AFRS(TM)), the first anatomic facet
reconstruction device designed to provide patients with lumbar spinal
stenosis, a motion preservation alternative to fusion.
Olson obtained a bachelor's degree in Behavioral Science and Health
Administration with a minor in Japanese from the University of Utah, together
with a master's-level internship from the same university.
"As we approach the commercialization of the first genetic prognostic test
for idiopathic scoliosis later this year, I am pleased that we have secured
such a talented and experienced sales and marketing professional as Eric
Olson" stated John M. Climaco, President and CEO. "He brings with him the
depth and breadth of spine-market experience that will assist us in
translating the benefits of our molecular diagnostic technology to surgeons
and patients around the world."
"I am convinced that Axial Biotech is in a position to change the way that
clinicians are able to treat Adolescent Idiopathic Scoliosis," said Olson. "I
am enthusiastic about the opportunity to help further the company to industry
leadership."
About Axial Biotech, Inc.
Axial Biotech, Inc. is a privately held, venture-backed company founded in
2002 by a group of internationally recognized spine surgeons and geneticists.
The company is focused on developing and commercializing DNA-based
pre-symptomatic and prognostic tests, as well as motion-preserving
technologies for common spinal disorders. The company's headquarter and
laboratory is located in Salt Lake City, Utah.
SOURCE Axial Biotech, Inc.
John M. Climaco, President and Chief Executive Officer of Axial Biotech, Inc.,
+1-801-984-9100, jclimaco@axialbiotech.com
